Drug class
Autologous CD34+ haematopoietic stem-cell gene therapy; lentiviral ARSA gene addition product
Mechanism of action
Autologous CD34+ cells are transduced ex vivo with a lentiviral vector encoding functional human arylsulfatase A (ARSA), then reinfused after conditioning. Transduced cells engraft and provide ARSA-expressing progeny, including myeloid-lineage cells, to restore enzyme activity and reduce sulfatide accumulation in the nervous system.
General use cases
- Treatment of selected presymptomatic late-infantile or early-juvenile and early-symptomatic early-juvenile metachromatic leukodystrophy (MLD) caused by biallelic ARSA mutations and deficient ARSA activity; eligibility depends on clinical stage and preserved function under the applicable product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
